Long‐acting PYY 3 −36 analogue with semaglutide for obesity: from preclinical assessment through randomized clinical studies
Authors' conclusion
PYY1875 showed modest efficacy as an add-on to semaglutide for weight management in people with obesity, but the treatment was not well tolerated.
Study context
- Population
- Obese male rats; participants with overweight or obesity
- Comparison
- PYY1875 alone or as add-on to semaglutide vs placebo
Methodological detailsplacebo-controlled
- Placebo-controlled
Primary result
As reported in the abstract
Treatment effect (phase 2)
- Modest but not clinically meaningful treatment effect of PYY1875 1.0 mg vs placebo as add-on to semaglutide 2.4 mg
Further findings
Body weight loss in semaglutide-treated obese rats
- PYY1875 induced additional body weight loss
Safety
Tolerability
- Phase 1: all doses of PYY1875 alone and with semaglutide were tolerated
- Phase 2: GI-related adverse events common with PYY1875 1.0 mg
- Phase 2: PYY1875 2.0-mg dose escalation regimen not tolerated
Original publication
Long‐acting PYY 3 −36 analogue with semaglutide for obesity: from preclinical assessment through randomized clinical studies. Obesity (Silver Spring). Published 8 July 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →